BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly reached pandemic proportions. Given that the main target of SARS-CoV-2 are lungs leading to severe pneumonia with hyperactivation of the inflammatory cascade, we conducted a prospective study to assess alveolar inflammatory status in patients with moderate to severe COVID-19. METHODS: Diagnostic bronchoalveolar lavage (BAL) was performed in 33 adult patients with SARS-CoV-2 infection by real-time PCR on nasopharyngeal swab admitted to the Intensive care unit (ICU) (nâ=â28) and to the Intermediate Medicine Ward (IMW) (nâ=â5). We analyze the differential cell count, ultrastructure of cells and Interleukin (IL)6, 8 and 10 levels. RESULTS: ICU patients showed a marked increase in neutrophils (1.24âÃâ10(5)âml(-â1), 0.85-2.07), lower lymphocyte (0.97âÃâ10(5)âml(-â1), 0.024-0.34) and macrophages fractions (0.43âÃâ10(5)âml(-â1), 0.34-1.62) compared to IMW patients (0.095âÃâ10(5)âml(-â1), 0.05-0.73; 0.47âÃâ10(5)âml(-â1), 0.28-1.01 and 2.14âÃâ10(5)âml(-â1), 1.17-3.01, respectively) (pâ<â0.01). Study of ICU patients BAL by electron transmission microscopy showed viral particles inside mononuclear cells confirmed by immunostaining with anti-viral capsid and spike antibodies. IL6 and IL8 were significantly higher in ICU patients than in IMW (IL6 pâ<â0.01, IL8 pâ<â0.0001), and also in patients who did not survive (IL6 pâ<â0.05, IL8 pâ=â0.05 vs. survivors). IL10 did not show a significant variation between groups. Dividing patients by treatment received, lower BAL concentrations of IL6 were found in patients treated with steroids as compared to those treated with tocilizumab (pâ<â0.1) or antivirals (pâ<â0.05). CONCLUSIONS: Alveolitis, associated with COVID-19, is mainly sustained by innate effectors which showed features of extensive activation. The burden of pro-inflammatory cytokines IL6 and IL8 in the broncho-alveolar environment is associated with clinical outcome.
Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
COVID-19 患者的支气管肺泡炎症:与临床结果的相关性
阅读:16
| 期刊: | BMC Pulmonary Medicine | 影响因子: | 2.800 |
| 时间: | 2020 | 起止号: | 2020 Nov 16; 20(1):301 |
| doi: | 10.1186/s12890-020-01343-z | 研究方向: | 炎症/感染 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。